@article{TCR8233,
author = {Daniel J. Felmlee and Thomas F. Baumert},
title = {CD147 handles lipid: a new role for anti-cancer target},
journal = {Translational Cancer Research},
volume = {5},
number = {3},
year = {2016},
keywords = {},
abstract = {The future of anti-cancer therapy is promising as immunotherapy strategies have been revolutionary in treatment of a number of cancers. However, some organs such as the liver are characterised by immunosuppression of CD4+ and CD8+ activity, necessitating alternative strategies for cancers in such tissues. This occurs at least partly through aberrant expression of alpha-fetoprotein that in turn dampens immune activation (1). Hepatocellular carcinoma (HCC) is the second leading cause of death from cancer worldwide (2). Complementary strategies to CD4+ and CD8+ T cell-mediated immunotherapies that specifically target HCC are needed for the future of effective and comprehensive cancer therapy. On the short-list for a molecular target for such a therapy is CD147/EMMPRIN.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8233}
}